CYTOMX THERAPEUTICS INC (CTMX) Fundamental Analysis & Valuation

NASDAQ:CTMX • US23284F1057

Current stock price

4.39 USD
+0.15 (+3.54%)
At close:
4.4122 USD
+0.02 (+0.51%)
After Hours:

This CTMX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CTMX Profitability Analysis

1.1 Basic Checks

  • CTMX had negative earnings in the past year.
  • In the past year CTMX has reported a negative cash flow from operations.
  • CTMX had negative earnings in 4 of the past 5 years.
  • CTMX had a negative operating cash flow in each of the past 5 years.
CTMX Yearly Net Income VS EBIT VS OCF VS FCFCTMX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • The Return On Assets of CTMX (-13.44%) is better than 79.30% of its industry peers.
  • CTMX has a Return On Equity of -20.57%. This is amongst the best in the industry. CTMX outperforms 81.24% of its industry peers.
Industry RankSector Rank
ROA -13.44%
ROE -20.57%
ROIC N/A
ROA(3y)4.24%
ROA(5y)-11.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTMX Yearly ROA, ROE, ROICCTMX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10K 20K

1.3 Margins

  • CTMX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTMX Yearly Profit, Operating, Gross MarginsCTMX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CTMX Health Analysis

2.1 Basic Checks

  • CTMX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CTMX has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, CTMX has more shares outstanding
  • CTMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CTMX Yearly Shares OutstandingCTMX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
CTMX Yearly Total Debt VS Total AssetsCTMX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • CTMX has an Altman-Z score of 2.41. This is not the best score and indicates that CTMX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • CTMX's Altman-Z score of 2.41 is fine compared to the rest of the industry. CTMX outperforms 65.57% of its industry peers.
  • CTMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.41
ROIC/WACCN/A
WACC9.19%
CTMX Yearly LT Debt VS Equity VS FCFCTMX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

2.3 Liquidity

  • CTMX has a Current Ratio of 3.09. This indicates that CTMX is financially healthy and has no problem in meeting its short term obligations.
  • CTMX's Current ratio of 3.09 is on the low side compared to the rest of the industry. CTMX is outperformed by 62.48% of its industry peers.
  • A Quick Ratio of 3.09 indicates that CTMX has no problem at all paying its short term obligations.
  • CTMX has a Quick ratio of 3.09. This is in the lower half of the industry: CTMX underperforms 60.15% of its industry peers.
Industry RankSector Rank
Current Ratio 3.09
Quick Ratio 3.09
CTMX Yearly Current Assets VS Current LiabilitesCTMX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CTMX Growth Analysis

3.1 Past

  • CTMX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -110.51%.
  • CTMX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -44.82%.
  • CTMX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.37% yearly.
EPS 1Y (TTM)-110.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-195.65%
Revenue 1Y (TTM)-44.82%
Revenue growth 3Y12.72%
Revenue growth 5Y-5.37%
Sales Q2Q%-98.26%

3.2 Future

  • Based on estimates for the next years, CTMX will show a very strong growth in Earnings Per Share. The EPS will grow by 27.49% on average per year.
  • Based on estimates for the next years, CTMX will show a very strong growth in Revenue. The Revenue will grow by 22.32% on average per year.
EPS Next Y-854.5%
EPS Next 2Y-205.73%
EPS Next 3Y-93.23%
EPS Next 5Y27.49%
Revenue Next Year-71.08%
Revenue Next 2Y-41.4%
Revenue Next 3Y-15.18%
Revenue Next 5Y22.32%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CTMX Yearly Revenue VS EstimatesCTMX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
CTMX Yearly EPS VS EstimatesCTMX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. CTMX Valuation Analysis

4.1 Price/Earnings Ratio

  • CTMX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CTMX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTMX Price Earnings VS Forward Price EarningsCTMX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTMX Per share dataCTMX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

  • CTMX's earnings are expected to decrease with -93.23% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-205.73%
EPS Next 3Y-93.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CTMX Dividend Analysis

5.1 Amount

  • CTMX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CTMX Fundamentals: All Metrics, Ratios and Statistics

CYTOMX THERAPEUTICS INC

NASDAQ:CTMX (4/10/2026, 8:15:16 PM)

After market: 4.4122 +0.02 (+0.51%)

4.39

+0.15 (+3.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-16
Earnings (Next)04-30
Inst Owners84.82%
Inst Owner Change0%
Ins Owners0.8%
Ins Owner Change4.28%
Market Cap743.84M
Revenue(TTM)76.20M
Net Income(TTM)-20.37M
Analysts86.67
Price Target13.9 (216.63%)
Short Float %13.19%
Short Ratio2.73
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-102.27%
Min EPS beat(2)-130.26%
Max EPS beat(2)-74.27%
EPS beat(4)2
Avg EPS beat(4)1.91%
Min EPS beat(4)-130.26%
Max EPS beat(4)113.47%
EPS beat(8)6
Avg EPS beat(8)88.65%
EPS beat(12)10
Avg EPS beat(12)92.37%
EPS beat(16)11
Avg EPS beat(16)63.53%
Revenue beat(2)0
Avg Revenue beat(2)-70.74%
Min Revenue beat(2)-91.77%
Max Revenue beat(2)-49.71%
Revenue beat(4)2
Avg Revenue beat(4)-13.96%
Min Revenue beat(4)-91.77%
Max Revenue beat(4)61.87%
Revenue beat(8)6
Avg Revenue beat(8)29.55%
Revenue beat(12)10
Avg Revenue beat(12)36.29%
Revenue beat(16)10
Avg Revenue beat(16)13.39%
PT rev (1m)47.3%
PT rev (3m)92.68%
EPS NQ rev (1m)-22.62%
EPS NQ rev (3m)-21.39%
EPS NY rev (1m)0%
EPS NY rev (3m)0.51%
Revenue NQ rev (1m)-25%
Revenue NQ rev (3m)-29.29%
Revenue NY rev (1m)-22.72%
Revenue NY rev (3m)-41.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.76
P/FCF N/A
P/OCF N/A
P/B 7.51
P/tB 7.62
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0.45
BVpS0.58
TBVpS0.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.44%
ROE -20.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)4.24%
ROA(5y)-11.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.99%
Cap/Sales 0.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.09
Quick Ratio 3.09
Altman-Z 2.41
F-Score2
WACC9.19%
ROIC/WACCN/A
Cap/Depr(3y)24.05%
Cap/Depr(5y)40.45%
Cap/Sales(3y)0.45%
Cap/Sales(5y)1.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-110.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-195.65%
EPS Next Y-854.5%
EPS Next 2Y-205.73%
EPS Next 3Y-93.23%
EPS Next 5Y27.49%
Revenue 1Y (TTM)-44.82%
Revenue growth 3Y12.72%
Revenue growth 5Y-5.37%
Sales Q2Q%-98.26%
Revenue Next Year-71.08%
Revenue Next 2Y-41.4%
Revenue Next 3Y-15.18%
Revenue Next 5Y22.32%
EBIT growth 1Y-189.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-706.07%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y12.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.34%
OCF growth 3YN/A
OCF growth 5YN/A

CYTOMX THERAPEUTICS INC / CTMX Fundamental Analysis FAQ

What is the fundamental rating for CTMX stock?

ChartMill assigns a fundamental rating of 3 / 10 to CTMX.


What is the valuation status for CTMX stock?

ChartMill assigns a valuation rating of 0 / 10 to CYTOMX THERAPEUTICS INC (CTMX). This can be considered as Overvalued.


Can you provide the profitability details for CYTOMX THERAPEUTICS INC?

CYTOMX THERAPEUTICS INC (CTMX) has a profitability rating of 1 / 10.